Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)

Mark T. Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore, Alexander Solms, Anita Shah, Pål André Holme, Lone H. Poulsen, Karina Meijer, Mindy Simpson, Maria Elisa Mancuso

Research output: Contribution to journalComment/debatepeer-review

Abstract

The graphic abstract was missing from this article and should have appeared as below. (Figure presented.) The original article has been corrected.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalDrugs in R and D
Volume25
Issue number1
DOIs
StatePublished - Mar 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)'. Together they form a unique fingerprint.

Cite this